Cannabidiol
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09061 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 48 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | restless legs syndrome | KG + DL |
| 2 | bilateral parasagittal parieto-occipital polymicrogyria | KG + DL |
| 3 | axial spondylometaphyseal dysplasia | KG + DL |
| 4 | amyotrophic lateral sclerosis | KG + DL |
| 5 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | KG + DL |
| 6 | episodic kinesigenic dyskinesia | KG + DL |
| 7 | Mills syndrome | KG + DL |
| 8 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 9 | lower motor neuron syndrome with late-adult onset | KG + DL |
| 10 | lethal arthrogryposis-anterior horn cell disease syndrome | KG + DL |
| 11 | monomelic amyotrophy | KG + DL |
| 12 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 13 | PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation | KG + DL |
| 14 | neonatal period electroclinical syndrome | KG + DL |
| 15 | 1q44 microdeletion syndrome | KG + DL |
| 16 | myoclonic epilepsy, Hartung type | KG + DL |
| 17 | genetic lethal multiple congenital anomalies/dysmorphic syndrome | KG + DL |
| 18 | autosomal dominant mitochondrial myopathy with exercise intolerance | KG + DL |
| 19 | infancy electroclinical syndrome | KG + DL |
| 20 | DK1-CDG | KG + DL |
| 21 | X-linked dominant intellectual disability-epilepsy syndrome | KG + DL |
| 22 | microtriplication 11q24.1 | KG + DL |
| 23 | CCDC115-CDG | KG + DL |
| 24 | colobomatous microphthalmia - obesity - hypogenitalism - intellectual disability syndrome | KG + DL |
| 25 | microcephaly-intellectual disability-phalangeal and neurological anomalies syndrome | KG + DL |
| 26 | defect in V-ATPase | KG + DL |
| 27 | neonatal epileptic encephalopathy | KG + DL |
| 28 | COG2-CDG | KG + DL |
| 29 | neonatal/infantile epilepsy syndrome | KG + DL |
| 30 | West syndrome | KG + DL |
| 31 | Jawad syndrome | KG + DL |
| 32 | febrile infection-related epilepsy syndrome | KG + DL |
| 33 | telecanthus-hypertelorism-strabismus-pes cavus syndrome | KG + DL |
| 34 | muscular hypertrophy-hepatomegaly-polyhydramnios syndrome | KG + DL |
| 35 | macrocephaly-short stature-paraplegia syndrome | KG + DL |
| 36 | microcephaly-short stature-intellectual disability-facial dysmorphism syndrome | KG + DL |
| 37 | pancreatic agenesis-holoprosencephaly syndrome | KG + DL |
| 38 | blepharophimosis - intellectual disability syndrome, MKB type | KG + DL |
| 39 | male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome | KG + DL |
| 40 | X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome | KG + DL |
| 41 | benign occipital epilepsy | KG + DL |
| 42 | malignant migrating partial seizures of infancy | KG + DL |
| 43 | craniofaciofrontodigital syndrome | KG + DL |
| 44 | arachnodactyly-abnormal ossification-intellectual disability syndrome | KG + DL |
| 45 | faciocardiorenal syndrome | KG + DL |
| 46 | Crane-Heise syndrome | KG + DL |
| 47 | XYLT1-CDG | KG + DL |
| 48 | perioral myoclonia with absences | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.